In temozolomide (TMZ)-resistant glioblastoma cells, NEDD4–1 contributes to redox imbalance by promoting PTEN degradation and activating the AKT/NRF2/HO-1 pathway, while I3C treatment suppresses tumorsphere formation, migration, and invasion in resistant cell lines (303). Here, NEDD4 is linked to glioblastoma.